Top Sector Life Sciences & Health (LSH) entails a broad scope of disciplines, from pharmaceuticals to medical technology and from healthcare infrastructure to vaccination. To realise its mission – vital citizens in a healthy economy - the Top Sector builds on the strengths of the Dutch LSH sector to address the biggest societal challenges in prevention, cure and care. By funding multidisciplinary public-private partnerships (PPPs) the Top Sector aims to facilitate innovation. Here we give an overview of  a number of funded R&D projects by Top Sector LSH. The page is updated continuously.

A live attenuated vaccine against coronaviruses

A live attenuated vaccine against coronaviruses: virological characterization of a challenge virus strain

This application builds on the previously granted TKI LSH project entitled “Construction of a toolbox of enabling technology for coronavirus vaccine strategies”. It involved the construction and testing of a novel type of live attenuated vaccine against coronaviruses.

Coronaviruses are well-known for their zoonotic potential and for their ability to cause deadly infections in humans (SARS-coronavirus, MERS-coronavirus etc.) as well as in animals, and for which no vaccines are yet available. Because testing of vaccine efficacy against such lethal viruses in humans is ethically not feasible, the approach was to develop a prototype vaccine against a lethal animal coronavirus, feline infectious peritonitis virus (FIPV).

Infections by FIPV result in severe systemic disease that is almost invariably fatal. It is the most dreaded infection among cat owners as there are no preventive or therapeutic measures. It is the aim to develop a vaccine against FIPV.

In this project, a FIPV challenge virus will be tested and characterised that will be used in future vaccination-challenge experiments.